Mortality in members of HIV-1 serodiscordant couples in Africa and implications for antiretroviral therapy initiation: results of analyses from a multicenter randomized trial

Guy de Bruyn, Amalia Magaret, Jared M Baeten, Jairam R Lingappa, Patrick Ndase, Connie Celum, Anna Wald, Partners in Prevention HSV/HIV Transmission Study Team, Guy de Bruyn, Amalia Magaret, Jared M Baeten, Jairam R Lingappa, Patrick Ndase, Connie Celum, Anna Wald, Partners in Prevention HSV/HIV Transmission Study Team

Abstract

Background: The risk of HIV-1 related mortality is strongly related to CD4 count. Guidance on optimal timing for initiation of antiretroviral therapy (ART) is still evolving, but the contribution of HIV-1 infection to excess mortality at CD4 cell counts above thresholds for HIV-1 treatment has not been fully described, especially in resource-poor settings. To compare mortality among HIV-1 infected and uninfected members of HIV-1 serodiscordant couples followed for up to 24 months, we conducted a secondary data analysis examining mortality among HIV-1 serodiscordant couples participating in a multicenter, randomized controlled trial at 14 sites in seven sub-Saharan African countries.

Methods: Predictors of death were examined using Cox regression and excess mortality by CD4 count and plasma HIV-1 RNA was computed using Poisson regression for correlated data.

Results: Among 3295 HIV serodiscordant couples, we observed 109 deaths from any cause (74 deaths among HIV-1 infected and 25 among HIV-1 uninfected persons). Among HIV-1 infected persons, the risk of death increased with lower CD4 count and higher plasma viral levels. HIV-1 infected persons had excess mortality due to medical causes of 15.2 deaths/1000 person years at CD4 counts of 250 - 349 cells/μl and 8.9 deaths at CD4 counts of 350 - 499 cells/μl. Above a CD4 count of 500 cells/μl, mortality was comparable among HIV-1 infected and uninfected persons.

Conclusions: Among African serodiscordant couples, there is a high rate of mortality attributable to HIV-1 infection at CD4 counts above the current threshold (200 - 350 cells/μl) for ART initiation in many African countries. These data indicate that earlier initiation of treatment is likely to provide clinical benefit if further expansion of ART access can be achieved.

Trial registration: Clinicaltrials.gov (NCT00194519).

Figures

Figure 1
Figure 1
Kaplan-Meier curve showing mortality with 95% CI caused by medical illness by participant serostatus.
Figure 2
Figure 2
Incidence of death by HIV-1 status and CD4 category for HIV-1-infected partners. Numbers above bars indicate the absolute number of deaths that occurred in each category

References

    1. Phillips AN, Elford J, Sabin C, Bofill M, Janossy G, Lee CA. Immunodeficiency and the risk of death in HIV infection. JAMA. 1992;268(19):2662–2666. doi: 10.1001/jama.1992.03490190062032.
    1. Severe P, Jean Juste MA, Ambroise A. et al.Early versus Standard Antiretroviral Therapy for HIV-Infected Adults in Haiti. N Engl J Med. 2010;363(3):257–265. doi: 10.1056/NEJMoa0910370.
    1. Kitahata MM, Gange SJ, Abraham AG. et al.Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360(18):1815–1826. doi: 10.1056/NEJMoa0807252.
    1. Sterne JA, May M, Costagliola D. et al.Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009;373(9672):1352–1363.
    1. Emery S, Neuhaus JA, Phillips AN. et al.Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197(8):1133–1144.
    1. Cohen MS, Chen YQ, McCauley M. et al.Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505. doi: 10.1056/NEJMoa1105243.
    1. World Health Organization. World Health Organization). Rapid advice: Antiretroviral therapy for HIV infection in adults and adolescents. , ; 2009. .
    1. Lodwick RK, Sabin CA, Porter K. et al.Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study. Lancet. 2010;376(9738):340–345.
    1. Brinkhof MWG, Boulle A, Weigel R. et al.Mortality of HIV-Infected Patients Starting Antiretroviral Therapy in Sub-Saharan Africa: Comparison with HIV-Unrelated Mortality. PLoS Med. 2009;6(4):e1000066. doi: 10.1371/journal.pmed.1000066.
    1. Hosegood V, Vanneste AM, Timaeus IM. Levels and causes of adult mortality in rural South Africa: the impact of AIDS. AIDS. 2004;18(4):663–671. doi: 10.1097/00002030-200403050-00011.
    1. Mermin J, Were W, Ekwaru JP. et al.Mortality in HIV-infected Ugandan adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet. 2008;371(9614):752–759. doi: 10.1016/S0140-6736(08)60345-1.
    1. Mwachari CW, Shepherd BE, Cleopa O, Odhiambo JA, Cohen CR. Mortality and burden of disease in a cohort of HIV-seropositive adults in Nairobi, Kenya. Int J STD AIDS. 2004;15(2):120–126. doi: 10.1258/095646204322764325.
    1. Senkoro KP, Boerma JT, Klokke AH. et al.HIV incidence and HIV-associated mortality in a cohort of factory workers and their spouses in Tanzania, 1991 through 1996. J Acquir Immune Defic Syndr. 2000;23(2):194–202.
    1. Urassa M, Boerma JT, Isingo R. et al.The impact of HIV/AIDS on mortality and household mobility in rural Tanzania. AIDS. 2001;15(15):2017–2023. doi: 10.1097/00002030-200110190-00015.
    1. Welaga P, Hosegood V, Weiner R, Hill C, Herbst K, Newell ML. Coming home to die? The association between migration and mortality in rural South Africa. BMC Public Health. 2009;9:193. doi: 10.1186/1471-2458-9-193.
    1. Hansen AB, Gerstoft J, Kronborg G, Pedersen C, Sorensen HT, Obel N. Mortality in siblings of patients coinfected with HIV and hepatitis C virus. J Infect Dis. 2007;195(2):230–235. doi: 10.1086/510246.
    1. Celum C, Wald A, Lingappa JR. et al.Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2. N Engl J Med. 2010;362(5):427–439. doi: 10.1056/NEJMoa0904849.
    1. Lingappa JR, Baeten JM, Wald A. et al.Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet. 2010;375(9717):824–833. doi: 10.1016/S0140-6736(09)62038-9.
    1. Lingappa JR, Kahle E, Mugo N. et al.Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study. PLoS One. 2009;4(4):e5272. doi: 10.1371/journal.pone.0005272.
    1. Lingappa JR, Lambdin B, Bukusi EA. et al.Regional Differences in Prevalence of HIV-1 Discordance in Africa and Enrollment of HIV-1 Discordant Couples into an HIV-1 Prevention Trial. PLoS One. 2008;3(1):e1411. doi: 10.1371/journal.pone.0001411.
    1. Diggle PJ, Heagerty PJ, Liang KY, Zeger SL. Analysis of Longitudinal Data. Oxford University Press, Oxford; 2002.
    1. Lehmann EL, Casella G. Theory of Point Estimation. 2. Springer, New York; 1998.
    1. The Antiretroviral Therapy in Lower Income Countries (ART-LINC) Collaboration ACCA-C. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–824.
    1. Hak E, Verheij TJ, Grobbee DE, Nichol KL, Hoes AW. Confounding by indication in non-experimental evaluation of vaccine effectiveness: the example of prevention of influenza complications. J Epidemiol Community Health. 2002;56(12):951–955. doi: 10.1136/jech.56.12.951.
    1. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(4):251–261. doi: 10.1016/S1473-3099(10)70026-8.
    1. Mellors JW, Munoz A, Giorgi JV. et al.Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126(12):946–954.
    1. HIV Surrogate Marker Collaborative Group. Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. AIDS Res Hum Retroviruses. 2000;16(12):1123–1133.
    1. The Mochudi Prevention Project ART Protocol. . , ; 2012. Accessed 30 Aug .
    1. Quinn TC, Wawer MJ, Sewankambo N. Rakai Project Study Group et al.Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med. 2000;342(13):921–929. doi: 10.1056/NEJM200003303421303.
    1. Lingappa JR, Hughes JP, Wang RS. et al.Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS One. 2010;5(9):e12598. doi: 10.1371/journal.pone.0012598.
    1. Jewkes R, Levin J, Penn-Kekana L. Risk factors for domestic violence: findings from a South African cross-sectional study. Soc Sci Med. 2002;55(9):1603–1617. doi: 10.1016/S0277-9536(01)00294-5.
    1. Braitstein P, Boulle A, Nash D. et al.Gender and the use of antiretroviral treatment in resource-constrained settings: findings from a multicenter collaboration. J Womens Health (Larchmt) 2008;17(1):47–55. doi: 10.1089/jwh.2007.0353.
    1. Mills EJ, Bakanda C, Birungi J. et al.Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med. 2011;155(4):209–216.
    1. Hanrahan CF, Golub JE, Mohapi L. et al.Body mass index and risk of tuberculosis and death. AIDS. 2010;24(10):1501–1508. doi: 10.1097/QAD.0b013e32833a2a4a.
    1. Madhavan S, Schatz E, Clark B. Effect of HIV/AIDS-related mortality on household dependency ratios in rural South Africa, 2000–2005. Popul Stud (Camb) 2009;63(1):37–51. doi: 10.1080/00324720802592784.
    1. Tsai AC, Chopra M, Pronyk PM, Martinson NA. Socioeconomic disparities in access to HIV/AIDS treatment programs in resource-limited settings. AIDS Care. 2009;21(1):59–63. doi: 10.1080/09540120802068811.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren